Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has issued an update.
On March 17, 2026, Pulse Biosciences announced a strategic realignment to prioritize development and future commercialization of its nPulse Cardiac Catheter Ablation System for atrial fibrillation, following unprecedented European feasibility data from more than 150 patients presented at the 31st Annual AF Symposium. The study reported 100% six‑month procedural success, 96% 12‑month durability, strong safety and efficiency metrics, prompting Pulse to shift capital and resources toward its electrophysiology catheter program while trimming near‑term sales and marketing spend and scaling back short‑term investments in cardiac surgery and soft‑tissue ablation to concentrate on this high‑value growth opportunity.
In the short term, the realignment will reduce headcount in sales and marketing, even as the company recruits into product development roles and prepares a pivotal IDE study and related regulatory submissions in the U.S. and Europe for the catheter platform. Pulse is maintaining commitment to Surgical Clamp IDE enrollment but lowering immediate market development spending in cardiac surgery, and is streamlining its percutaneous soft‑tissue ablation operations to focus Vybrance system development on benign thyroid nodules and reimbursement validation, freeing capital to reinforce its position in the competitive electrophysiology market for AFib treatment.
The most recent analyst rating on (PLSE) stock is a Hold with a $20.50 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, widening losses, and higher cash burn) and limited valuation support (negative P/E, no dividend). Offsetting factors include constructive technical positioning versus longer-term moving averages and positive clinical/regulatory progress and guidance from the latest earnings call, though funding and commercialization timing remain key risks.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse technology, which uses Nanosecond Pulsed Field Ablation to non-thermally clear cells while sparing adjacent noncellular tissue. The company focuses on treating atrial fibrillation with catheter-based electrophysiology systems and on select soft-tissue ablation markets, including surgical and percutaneous applications.
Average Trading Volume: 328,111
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.48B
For detailed information about PLSE stock, go to TipRanks’ Stock Analysis page.